Sign In
Buy AKBA
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript
12:35pm, Friday, 06'th Nov 2020
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 03'rd Nov 2020
CAMBRIDGE, Mass., Nov. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted
Packaging Machinery Market Procurement Intelligence Report With COVID-19 Impact Analysis | Global Forecasts, 2020-2024 | SpendEdge
12:00am, Tuesday, 20'th Oct 2020
Packaging Machinery market will register an incremental spend of about USD 17 billion, growing at a CAGR of 6.37% during the five-year forecast period
Packaging Machinery Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024
12:00am, Friday, 18'th Sep 2020
The Packaging Machinery market will register an incremental spend of about $17 billion, growing at a CAGR of 6.37%
Akebia Anemia Data, And Other News: The Good, Bad And Ugly Of Biopharma
11:16pm, Sunday, 06'th Sep 2020
Akebia reports data for its anemia drug candidate. Abbott moves ahead with Drug-Eluting resorbable scaffold.
Wall Street Breakfast: The Week Ahead
09:35am, Saturday, 05'th Sep 2020
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Tracking Seth Klarman's Baupost Group Holdings - Q2 2020 Update
08:00am, Saturday, 15'th Aug 2020
Seth Klarman’s 13F portfolio value increased from $6.77B to $8.01B this quarter. Baupost Group increased Atara Biotherapeutics while dropping Cheniere Energy.
Tracking David Abrams' Abrams Capital Management Portfolio - Q2 2020 Update
08:56am, Friday, 14'th Aug 2020
David Abrams' 13F portfolio value increased this quarter from $2.54B to $3.09B. The number of positions decreased from 22 to 20.
If You Had Bought Akebia Therapeutics (NASDAQ:AKBA) Stock A Year Ago, You Could Pocket A 132% Gain Today
11:08am, Wednesday, 12'th Aug 2020
While Akebia Therapeutics, Inc. (NASDAQ:AKBA) shareholders are probably generally happy, the stock hasn't had...
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Path To Profitability
11:07am, Wednesday, 12'th Aug 2020
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA): Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the...
Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates
09:55pm, Monday, 10'th Aug 2020
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 4.35% and 18.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Akebia Reports Second Quarter 2020 Financial Results
08:01pm, Monday, 10'th Aug 2020
Top-line data readout of global Phase 3
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Were Hedge Funds Right About Warming Up To Akebia Therapeutics Inc (AKBA)?
01:30pm, Friday, 07'th Aug 2020
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes
Astellas Pharma's (ALPMF) Management on Q1 2021 Results - Earnings Call Transcript
08:18pm, Tuesday, 04'th Aug 2020
Astellas Pharma Inc (OTCPK:ALPMF) Q1 2021 Earnings Conference Call August 04, 2020 3:00 AM ET Company Participants Naoki Okamura – Representative Director and Executive Vice President Mike Kitagawa
